FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> GlaxoSmithKline | India

Report: GlaxoSmithKline in talks to buy India vaccine unit

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

India's Economic Times is reporting that GlaxoSmithKline Biologicals, a division of GSK, is in talks to acquire Hyderabad-based Biological E's vaccine division. Sources say executives from GSK's Belgium-based unit have visited the India company's manufacturing facility, though talks are preliminary. The India vaccine company makes both pediatric and adult vaccines and possess a sizeable share of India's vaccine market. Its lead products prevent Diphtheria and tetanus.

An unnamed analyst tells the Times that constraints at GSK's plant in Nashik, Maharashtra has caused the company to struggle with its vaccine supply. The BE vaccine unit buyout would give GSK additional capacity in the country. The analyst also observed that the BE's experience with pediatric vaccines would compliment GSK Biologicals' already huge business in that area.

- read the Economic Times report

Related Articles:
GSK's India strategy could come full circle
GSK moves bioprocessing to UK from India
GSK stakes claim in emerging-markets 'land grab'


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about GlaxoSmithKline   India